Synthetic educational example. Do not self-treat: a qualified treating physician must verify the sources, patient data, contraindications, and final plan.
Patient
BMA-HRD_STATUS_PROSTATE · Algorithm: ALGO-PROSTATE-MCRPC-1L
Clinical significance of mutations (ESCAT)
Tumor-board context — the engine does not use these tiers to rank tracks
| Biomarker | Variant | ESCAT | Evidence | Clinical significance | Drugs | Sources |
|---|
| No clinically actionable variants matched in this profile. |
| Biomarker | Status |
|---|
| BIO-HRD-STATUS | BIO definition in KB; no ESCAT BMA entry — verify with clinician |
Primary current-line option
- Indication
- IND-PROSTATE-MCRPC-1L-ARPI
- Regimen
- ADT + enzalutamide (continuous)
- Drugs + NSZU
- Leuprolide (DRUG-LEUPROLIDE) 11.25 mg IM q3 months · Continuous · IM ✓ NSZU covered
- Enzalutamide (DRUG-ENZALUTAMIDE) 160 mg PO daily · Continuous · PO ✓ NSZU covered
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Primary current-line option selected by ALGO-PROSTATE-MCRPC-1L at step 4.
Other current-line alternatives (2 tracks)
Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.
- Indication
- IND-PROSTATE-MCRPC-1L-PARPI
- Regimen
- Olaparib monotherapy (mCRPC, HRR-mutant)
- Drugs + NSZU
- Olaparib (DRUG-OLAPARIB) 300 mg PO BID continuous · Until progression or unacceptable toxicity · PO ⚠ NSZU — not for this indication
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-PROSTATE-MCRPC-2L-LU-PSMA
- Regimen
- Lutetium-177 PSMA-617 radioligand therapy
- Drugs + NSZU
- Lutetium-177 PSMA-617 (DRUG-LUTETIUM-177-PSMA) 7.4 GBq IV · q6 weeks × 6 cycles · IV ✗ Not registered in UA
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Current-line alternative presented for HCP consideration
Pre-treatment investigations
Investigations before treatment start · critical / standard / desired · merged across tracks
| ID | Name | Priority | Category | Where to order | Needed for |
|---|
| TEST-CBC | Complete Blood Count with Differential | Critical | lab | — | standard |
| TEST-CMP | Comprehensive Metabolic Panel | Critical | lab | — | standard |
| TEST-PSA-SERUM | Serum PSA | Critical | — | — | all tracks |
| TEST-BONE-SCAN | Whole-body Tc-99m MDP bone scintigraphy | Standard | — | — | all tracks |
| TEST-GERMLINE-BRCA-PANEL | Germline BRCA1/2 + HRR panel sequencing | Standard | — | CSD Lab: M089 | all tracks |
| TEST-PSMA-PET | PSMA-PET/CT (Ga-68 or F-18) | Standard | — | — | standard |
| TEST-SOMATIC-HRR-PANEL | Tumor-tissue (or ctDNA) HRR-pathway NGS panel | Standard | — | CSD Lab: M065
CSD Lab ✓ (code TBC) | aggressive |
| TEST-TESTOSTERONE-SERUM | Serum total testosterone | Standard | — | — | all tracks |
Red flags — PRO / CONTRA aggressive
PRO-AGGRESSIVE
Triggers that push toward the aggressive track
- AR (androgen receptor) gene amplification detected on tumor or ctDNA NGS in mCRPC — INFORMATIONAL signal of mechanistic ARSI resistance. AR amplification is one of the most common acquired resistance mechanisms to abiraterone / enzalutamide / apalutamide / darolutamide; detected in ~30-50% of post-ARSI mCRPC ctDNA samples. AR-amp argues against ARSI-after-ARSI sequencing (limited cross-class benefit) and for early switch to taxane chemotherapy (docetaxel, cabazitaxel) or radioligand 177Lu-PSMA-617 (if PSMA-PET-positive). FDA has NOT approved any therapy decision keyed on AR-amp status — surfaces in MDT brief to flag patients in whom further ARSI escalation is unlikely to add benefit. Companion to RF-PROSTATE-AR-V7-ARSI-RESISTANCE (AR-V7 splice variant); both detect distinct facets of AR-driven resistance.
References BIO-AR-AMPLIFICATION. Detection: ctDNA NGS (Guardant360, FoundationOne Liquid CDx) is the practical platform — tumor biopsy in mCRPC frequently fails (bone-only disease, low cellularity). Co-occurring resistance markers include…
RF-PROSTATE-AR-AMP-ARSI-RESISTANCESRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024SRC-EAU-PROSTATE-2024 - AR-V7 (androgen receptor splice variant 7) detected in CTCs / ctDNA in mCRPC — predictive marker of ARSI (abiraterone, enzalutamide, apalutamide, darolutamide) failure. PROPHECY (Antonarakis 2019): AR-V7-positive on Epic CTC IHC associated with HR ~3 for inferior PFS/OS on ARSI vs AR-V7-negative; switch to taxane (docetaxel, cabazitaxel) recovers responses. INFORMATIONAL — FDA has NOT approved any therapy decision keyed on AR-V7; surfaces in MDT brief to flag patients in whom ARSI-after-ARSI is unlikely to work.
Detection: Epic AR-V7 Nucleus Detect (CTC-IHC) is the most-validated platform; requires ≥5 CTC per 7.5 mL blood for an interpretable result (lower CTC counts are non-informative, not negative). Alternatives: PCR-based AR-V7 mRNA on CTCs…
RF-PROSTATE-AR-V7-ARSI-RESISTANCESRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Metastatic prostate cancer with malignant epidural spinal cord compression (MESCC): new motor deficit, sensory level, cauda equina syndrome, severe back pain with vertebral metastasis — prostate is the most common solid tumor cause of MESCC
Per NCCN-PROSTATE supportive-care + EAU-PROSTATE 2024: dexamethasone 10 mg IV bolus + 4 mg q6h, MRI whole spine within 24 h, multidisciplinary surgical/RT review. Patchell criteria for surgery (single-level, ≥48 h expected survival…
RF-PROSTATE-CORD-COMPRESSIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024SRC-EAU-PROSTATE-2024 - Germline or somatic BRCA1/2 mutation OR broader HRR pathway alteration (ATM, CDK12, PALB2, etc.) — predicts PARPi response; opens olaparib/talazoparib indication in mCRPC.
PROfound (olaparib) + TALAPRO-2 (talazoparib + enzalutamide) + MAGNITUDE (niraparib + abiraterone) define PARPi indications. BRCA1/2 largest benefit; broader HRR cohort smaller but positive. Germline + somatic testing recommended for ALL…
RF-PROSTATE-HIGH-RISK-BIOLOGYSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Pre-treatment HBV/HCV/HIV serology + dental evaluation (denosumab/zoledronate ONJ risk; lutetium-PSMA xerostomia) standard for mCRPC initiation.
Cross-disease HBV reactivation handled by RF-UNIVERSAL-HBV-REACTIVATION- RISK. Dental clearance pre-bone-modifying-agent unique to bone-meta diseases (prostate, breast, MM).
RF-PROSTATE-INFECTION-SCREENINGSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Renal dysfunction (CrCl <50 mL/min) or severe hepatic impairment (Child-Pugh C) — limits PARPi (olaparib renal-cleared) and ARPI (abiraterone hepatic) dosing.
Olaparib requires CrCl ≥31 (with dose-mod) for safe use; <30 avoid. Abiraterone Child-Pugh C: avoid. Surfaces in MDT as need for renal/ hepatic input.
RF-PROSTATE-ORGAN-DYSFUNCTIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - PCWG3-defined PSA progression on systemic prostate-cancer therapy: ≥25% rise from nadir + ≥2 ng/mL absolute increase, confirmed by a second value ≥3 weeks later. Triggers re-imaging + MDT consideration of next-line therapy switch — but NOT alone sufficient to change line if radiographic + clinical disease stable (per PCWG3 + STAR criteria).
PSA-only progression on ARPI / chemotherapy is common (~30-40% of patients show PSA flare or transient rise). PCWG3 explicitly cautions against line switch on PSA alone — radiographic progression (RECIST 1.1 for soft tissue, PCWG3…
RF-PROSTATE-PSA-PROGRESSIONSRC-NCCN-PROSTATE-2025SRC-EAU-PROSTATE-2024 - Spinal cord compression OR rapid PSA doubling time (<3 months) OR new visceral metastases — emergency or aggressive-progression flag requiring urgent intervention or treatment intensification.
Spinal cord compression: emergent neurosurgical / RT consult AND immediate testosterone suppression (degarelix preferred for speed vs LHRH agonists). PSA doubling time <3 months in nmCRPC: criterion for ARPI initiation per NCCN. Visceral…
RF-PROSTATE-TRANSFORMATION-PROGRESSIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024
CONTRA-AGGRESSIVE
Hard contraindications to escalation
What NOT to do
Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Standard plan (IND-PROSTATE-MCRPC-2L-LU-PSMA)
- НІКОЛИ не призначати без PSMA-ПЕТ/КТ-підтвердження — тільки PSMA-позитивна хвороба
- Не призначати при будь-якому PSMA-негативному осередку метастазування
- Не ігнорувати ниркову функцію — лютецій виводиться нирками; ГФК <30 = протипоказання
- Не пропускати тестування HRR/BRCA до призначення — PARPi перевершує при BRCA1/2
- Не призначати без підтримки ядерно-медичного відділу з радіотерапевтичною ліцензією
Timeline
Treatment timeline — derived from regimen + monitoring schedule
Standard plan
Induction · ADT + enzalutamide (continuous)
28-day cycles × Continuous until progression or unacceptable toxicity
Aggressive plan
Induction · Olaparib monotherapy (mCRPC, HRR-mutant)
28-day cycles × Continuous until progression
Standard plan
Induction · Lutetium-177 PSMA-617 radioligand therapy
42-day cycles × 6 (extend to 8 if responding and tolerated, per protocol)
MDT brief
Discussion questions (5, 2 blocking)
OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
BLOCKING OQ-BIOMARKER-GLEASON-ISUP
What is the status of Gleason score / ISUP grade group (BIO-GLEASON-ISUP)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
BLOCKING OQ-BIOMARKER-PSA
What is the status of Prostate-specific antigen (PSA) (BIO-PSA)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
OQ-BIOMARKER-HRR-PANEL
What is the status of Homologous recombination repair (HRR) gene panel status (BIO-HRR-PANEL)? It is required by track(s): IND-PROSTATE-MCRPC-1L-PARPI. Expected value: positive.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ molecular_geneticist
OQ-BIOMARKER-PSMA-PET
What is the status of PSMA-PET imaging avidity (BIO-PSMA-PET)? It is required by track(s): IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred).
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
MDT talk tree (6 steps)
| # | Owner | Topic | Action |
|---|
| 1 | medical_oncologist | Biomarker status BLOCKING | What is the status of Gleason score / ISUP grade group (BIO-GLEASON-ISUP)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications. |
| 2 | medical_oncologist | Biomarker status BLOCKING | What is the status of Prostate-specific antigen (PSA) (BIO-PSA)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications. |
| 3 | hematologist | Staging / disease burden | What is the current LDH? Marker of tumor burden and transformation. |
| 4 | medical_oncologist | Biomarker status | What is the status of PSMA-PET imaging avidity (BIO-PSMA-PET)? It is required by track(s): IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred). |
| 5 | molecular_geneticist | Biomarker status | What is the status of Homologous recombination repair (HRR) gene panel status (BIO-HRR-PANEL)? It is required by track(s): IND-PROSTATE-MCRPC-1L-PARPI. Expected value: positive. |
| 6 | clinical_pharmacist | Specialist review | Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication. |
Skills (recommended) — for consideration (2)
- Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
- Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
Owns: OQ-BIOMARKER-HRR-PANEL
Data quality
Incomplete for default-track review. Default-track review is incomplete until required biomarker gaps are resolved.
- Biomarker coverage: 0/4 known (0%), 4 missing, 2 default-track gaps
- Unevaluated RedFlags: RF-ATM-CONFIRMED-CARRIER, RF-ATM-FAMILY-HISTORY-SUSPICION, RF-BRCA-CONFIRMED-CARRIER, RF-BRCA-HBOC-FAMILY-HISTORY-SUSPICION, RF-CASCADE-BRCA-FDR-POSITIVE, RF-CASCADE-FAP-FDR-POSITIVE, RF-CASCADE-LYNCH-FDR-POSITIVE, RF-CHAARTED-HIGH-VOLUME-MHSPC, RF-CHEK2-CONFIRMED-CARRIER, RF-CHEK2-FAMILY-HISTORY-SUSPICION, RF-FAP-FAMILY-HISTORY-SUSPICION, RF-LATITUDE-HIGH-RISK-MHSPC, RF-LYNCH-CONFIRMED-CARRIER, RF-LYNCH-FAMILY-HISTORY-SUSPICION, RF-PAN-ATM-CHEK2-CDK12-PARPI-CANDIDATE, RF-PAN-BRCA-SOMATIC-PARPI-CANDIDATE, RF-PAN-PALB2-PARPI-CANDIDATE, RF-PROSTATE-AR-AMP-ARSI-RESISTANCE, RF-PROSTATE-AR-V7-ARSI-RESISTANCE, RF-PROSTATE-CORD-COMPRESSION, RF-PROSTATE-FRAILTY-AGE, RF-PROSTATE-HIGH-RISK-BIOLOGY, RF-PROSTATE-INFECTION-SCREENING, RF-PROSTATE-ORGAN-DYSFUNCTION, RF-PROSTATE-PSA-PROGRESSION, RF-PROSTATE-TMPRSS2-ERG-PROGNOSTIC, RF-PROSTATE-TRANSFORMATION-PROGRESSION
| Missing biomarker | Label | MDT owner | Default track | Required by | Next action |
|---|
BIO-GLEASON-ISUP | Gleason score / ISUP grade group | medical_oncologist | yes | IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications |
BIO-PSA | Prostate-specific antigen (PSA) | medical_oncologist | yes | IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications |
BIO-HRR-PANEL | Homologous recombination repair (HRR) gene panel status | molecular_geneticist | no | IND-PROSTATE-MCRPC-1L-PARPI | Verify result, method, specimen, and report date before sign-off. Expected/constraint: positive |
BIO-PSMA-PET | PSMA-PET imaging avidity | medical_oncologist | no | IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred) |
Technical MDT skill metadata (2/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
| Specialist | skill_id | Version | Last reviewed | Sign-offs | Domain |
|---|
| Cellular therapy specialist (CAR-T) | cellular_therapy_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
| Clinical pharmacist | clinical_pharmacist | v0.1.0 | 2026-04-25 | 0 | clinical_pharmacy |
| Hematologist / oncohematologist | hematologist | v0.1.0 | 2026-04-25 | 0 | hematology_oncology |
| Hematopathologist (lymphoma / leukemia / myeloma) | hematopathologist | v0.1.0 | 2026-04-25 | 0 | hematopathology |
| Infectious disease / hepatology | infectious_disease_hepatology | v0.1.0 | 2026-04-25 | 0 | infectious_diseases |
| Medical oncologist (solid-tumor chemotherapist) | medical_oncologist | v0.1.0 | 2026-04-25 | 0 | solid_oncology |
| Molecular geneticist / molecular oncologist | molecular_geneticist | v0.1.0 | 2026-04-25 | 0 | molecular_oncology |
| Palliative care | palliative_care | v0.1.0 | 2026-04-25 | 0 | palliative_care |
| Pathologist (general) | pathologist | v0.1.0 | 2026-04-25 | 0 | pathology |
| Primary care / family physician | primary_care | v0.1.0 | 2026-04-25 | 0 | primary_care |
| Psycho-oncologist | psychologist | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Radiation oncologist | radiation_oncologist | v0.1.0 | 2026-04-25 | 0 | radiation_oncology |
| Radiologist | radiologist | v0.1.0 | 2026-04-25 | 0 | diagnostic_imaging |
| Social worker / case manager | social_worker_case_manager | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Surgical oncologist | surgical_oncologist | v0.1.0 | 2026-04-25 | 0 | surgical_oncology |
| Transplant specialist (BMT) | transplant_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
Sources cited
- SRC-ESMO-PROSTATE-2024: ESMO Clinical Practice Guideline on Prostate Cancer (2024)
- SRC-NCCN-PROSTATE-2025: NCCN Clinical Practice Guidelines — Prostate Cancer (2025.v3)
- SRC-VISION-PSMA-SARTOR-2021: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021)
Experimental options (clinical trials)
Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-08-18.
| NCT | Title | Phase | Status | Sponsor | UA | Signals | Eligibility (excerpt) |
|---|
| NCT06610825 | Castrate Resistant Prostate Cancer Enhertu Therapy | PHASE2 | RECRUITING | — | Surrogate endpoint only Single country | |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | PHASE1 | RECRUITING | — | Phase 1 only | |
| NCT06822036 | EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER | NA | RECRUITING | — | Single country | |
| NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | PHASE2 | RECRUITING | — | Single country | |
| NCT06022822 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | PHASE2 | RECRUITING | — | Single country | |
| NCT06774781 | Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions | N/A | RECRUITING | — | Single country | |
| NCT06392295 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer | PHASE2 | RECRUITING | — | Small N (<50) Surrogate endpoint only Single country | |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | PHASE3 | RECRUITING | — | — | |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | PHASE2 | RECRUITING | — | Single country | |
| NCT05022914 | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE | N/A | RECRUITING | — | Surrogate endpoint only Single country | |
Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.
Option availability in Ukraine
Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
| Option | UA registration | NSZU | Cost orientation | Access pathway |
|---|
| Standard plan ADT + enzalutamide (continuous) (REG-ADT-ENZALUTAMIDE) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan Olaparib monotherapy (mCRPC, HRR-mutant) (REG-OLAPARIB-MONO) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Standard plan Lutetium-177 PSMA-617 radioligand therapy (REG-LUTETIUM-PSMA) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Trial · NCT06610825 Castrate Resistant Prostate Cancer Enhertu Therapy No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05176483 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06822036 EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06134232 Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06022822 Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06774781 Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06392295 PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06592924 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06173362 Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05022914 PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-08-18.